HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of ca...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Ende, Nadine S., Smid, Marcel, Timmermans, Annemieke, van Brakel, Johannes B., Hansum, Tim, Foekens, Renée, Trapman, Anita M. A. C., Heemskerk-Gerritsen, Bernadette A. M., Jager, Agnes, Martens, John W. M., van Deurzen, Carolien H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334272/
https://www.ncbi.nlm.nih.gov/pubmed/35902644
http://dx.doi.org/10.1038/s41598-022-16898-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334272/
https://www.ncbi.nlm.nih.gov/pubmed/35902644
http://dx.doi.org/10.1038/s41598-022-16898-6

Ejemplares similares